



# ROTEM *delta* system



Redefining Bleeding Control



**Instrumentation  
Laboratory**

A Werfen Company

# ROTEM *delta* analyzer



In patients exhibiting clinically significant bleeding, ROTEM systems can quickly help to identify an underlying coagulopathy and guide appropriate decisions toward individualized and goal-directed therapy.

Uses **four self-calibrating channels** and citrated whole blood to demonstrate *in vitro* the presence and/or functionality of enzymatic clotting factors, cofactors, and substrates involved in whole-blood clot formation and fibrinolysis.

## Easy and safe handling

- Touchscreen user interface
- Automated pipette with on-screen prompts
- Simple patient ID search function for fast and safe real-time data transmission

## Easy, intuitive touchscreen interface

ROTEM® Measurement module							
Preparation	Multi-TEM	Screenshot	Standard overlay	Patient overlay		Help	Quit
Last name: <input type="text"/> First name: <input type="text"/> Patient ID: <input type="text" value="12083321"/> Sample ID: <input type="text"/>							
Put a NEW tip into the gently mixed citrated blood sample and confirm							
INTEM		EXTEM		FIBTEM		APTEM	
3: 12083321 ST: --- RT: --- CT: --- CFT: --- α: --- A10: ---		1: John, Doe ST: --- RT: --- CT: --- CFT: --- α: --- A10: ---		1: John, Doe ST: --- RT: --- CT: --- CFT: --- α: --- A10: ---		1: John, Doe ST: --- RT: --- CT: --- CFT: --- α: --- A10: ---	
2013-05-06T14:33:57 v2.2.0 User: admin						Temperature: 37.0°C Pre 1 2 3 4	

# Advanced technology and support



## Technology

- ROTEM technology features rotating pin and stationary cup
- Stabilized ball-bearing technology prevents sensitivity to shock and vibration
- 24-hour, internal mechanical monitoring


## Support

- Reference ranges available, based on independent, multi-center study in US
- ROTEM trolley offers mobile versatility for use in satellite or central labs
- USB printer
- Integrated scanner for adding patient information

### ROTEM trolley



### ROTEM technology



# Comprehensive liquid reagent portfolio



## A comprehensive liquid reagent portfolio to support differential diagnosis

Five specific ROTEM assays allow for differential diagnosis

	in-tem	ex-tem	fib-tem	ap-tem	hep-tem
Function	Pathway-specific information	Pathway-specific information	Isolates and assesses fibrinogen contributor	Determines antifibrinolytic effect	Demonstrates heparin effect and reversal
Benefit	Fast assessment of clot formation, fibrin polymerization and fibrinolysis via the intrinsic pathway	Fast assessment of clot formation, fibrin polymerization and fibrinolysis via the extrinsic pathway	Analysis without platelets; qualitative assessment of fibrinogen status	fast detection of lysis (compared to ex-tem); <i>in vitro</i> fibrinolysis inhibition	For specific detection of heparin (compared to in-tem)

## Liquid quality controls

	ROTROL N	ROTROL P
Indication	Quality control material for monitoring accuracy and precision of tests in the normal range on the ROTEM <i>delta</i> system	Quality control material for monitoring accuracy and precision of tests in the abnormal range on the ROTEM <i>delta</i> system



# Fast therapeutic decisions




## Results from ROTEM analysis can guide optimal treatment and monitor within minutes

- ROTEM analysis starts immediately after sample introduction, with first results in 5-10 minutes
- Early amplitude values (A10)
- Real-time, bedside results and remote viewing capabilities allow faster patient management decisions
- Four independent channels allow differential diagnosis of coagulopathies
- Easy therapeutic control using previous patient results as an overlay
- Standard curve overlays enable fast, visual interpretation
- Simplified interpretation of results via color-coded TEMograms and highlighted abnormal parameter results

## TEMograms


The shapes of the TEMograms (curves) and published reference parameters allow clinicians to make a better determination of hemostasis and targeted therapy choices to stop bleeding.

### ROTEM *delta* TEMogram



CT Clotting time  
CFT Clot formation time  
A10 Amplitude 10 min. after CT  
MCF Maximum clot firmness  
LI30 Lysis index 30 min. after CT  
ML Maximum Lysis


### Four-channel TEMograms



# ROTEM *delta* data solutions

## Data solutions optimize ROTEM *delta* functionality

- Access patient results anywhere
- View results remotely via local network
- Network up to 10 ROTEM *delta* systems
- Easy to deploy and administer on hospital network
- Meets HIPAA/HITECH security standards
- Uses secure, closed, Linux-based systems



ROTEM *delta* analyzer provides rapid and more complete hemostasis information.

### Literature

- Haas T, *et al.* Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. *Minerva Anesthesiol.* 2014;80(12):1320-35.
- Corredor C, *et al.* The role of point-of-care platelet function testing in predicting postoperative bleeding following cardiac surgery: a systematic review and meta-analysis. *Anaesthesia.* 2015;70(6):715-31.
- American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. *Anesthesiology.* 2015;122(2):241-75.
- Kirchner C, *et al.* Coagulation management with factor concentrates in liver transplantation: a single-center experience. *Transfusion.* 2014;54(10 Pt 2):2760-8.
- Theusinger OM, *et al.* Rotation thromboelastometry (ROTEM) stability and reproducibility over time. *Eur J Cardiothorac Surg.* 2010;37(3):677-83.
- Anderson L, *et al.* Interoperator and Intraoperator Variability of Whole Blood Coagulation Assays: A Comparison of Thromboelastography and Rotational Thromboelastometry. *J of Cardiothoracic and Vascular Anesthesiology.* 2014;28(6):1550-7.
- Hagemo JS, *et al.* Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. *Crit Care.* 2015;19:97.
- Schöchl H, *et al.* Early and individualized goal-directed therapy for trauma-induced coagulopathy. *Scand J Trauma Resusc Emerg Med.* 2012;20(1):15.
- Görlinger K and Kozek-Langenecker SA. Economic aspects and organization. In: Marcucci E and Schoettker P (eds.). *Perioperative Hemostasis - Coagulation for Anesthesiologists.* Springer, Berlin, Heidelberg, 2015:421-5.
- Weber CF, *et al.* Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. *Anesthesiology.* 2012;117(3):531-47.
- Karkouti K, *et al.* Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. *Anesthesiology.* 2015;122(3):560-70.
- Larsen OH, *et al.* Diagnostic Performance and Therapeutic Consequence of Thromboelastometry Activated by Kaolin versus a Panel of Specific Reagents. *Anesthesiology.* 2011;115:294-302.

The Instrumentation Laboratory logo, ACL, ACL AcuStar, ACL Elite, ACL TOP, HemoCell, HemoHub, HemosIL, ReadipLasTin, RecombiLasTin and SynthASil are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos and symbols are trademarks of their respective owners.

©2017 Instrumentation Laboratory. 180 Hartwell Road, Bedford, MA 01730 USA. All rights reserved.